Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Shares of biotech company Regeneron (NASDAQ:REGN)
jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key treatments, including its eye care therapy Eylea HD, cancer drug Libtayo, and immunology medicine Dupixent, which all recorded substantial sales increases.
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.
Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B.
TARRYTOWN, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update.
